Skip to main content
HCPCS J0217 · Level II · Part B drug

J0217: velmanase alfa-tycv (Lamzede), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0217

Billing unit
1 MG
Inj velmanase alfa-tycv 1 mg
ASP payment limit
$479.191
October 2026; +0.0% vs July 2026
Practitioner MUE
150
MAI 3
OPPS status
SI G
APC 0710
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J0217 is the Level II code for Injection, velmanase alfa-tycv, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $479.191 per billing unit, up 0.0% from July 2026. The practitioner MUE allows up to 150 units per date of service (MAI 3), so a full 150-unit day is $71,878.65 at the current limit. Under OPPS it carries status indicator G in APC 0710. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 1 NDC to it, sold as Lamzede by Chiesi USA, Inc. No current Billing and Coding Article lists J0217, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0217 at $479.191 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $479.191 in July 2026. Beneficiary coinsurance is 19%.

ASP payment limits for J0217
QuarterPayment limitPerCoinsurance
October 2026$479.1911 MG19%
July 2026$479.1911 MG—
CMS note: Inflation-adjusted coinsurance

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J0217. Report the NDC in the claim's drug segment and bill the number of J0217 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J0217
NDCDrug nameLabelerPackage sizeBilling units / package
10122-0180-02LamzedeChiesi USA, Inc.1 × 110

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J0217. For practitioners the limit is 150 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J0217 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1503 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J0217 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0217 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0217 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0217 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J0217 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0217 carries status indicator G and is assigned to APC 0710, with a published national unadjusted payment of $479.191. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0217 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $479.19 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure. Pass-through status expires *.

Common denials for J0217 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0217

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0217

What does HCPCS code J0217 describe?

J0217 is defined by CMS as "Injection, velmanase alfa-tycv, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0217 a CPT code?

No. J0217 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as velmanase alfa-tycv (Lamzede); CPT codes are five-character codes maintained by the AMA. On a Part B claim J0217 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0217 in October 2026?

The ASP-based payment limit is $479.191 per 1 MG, with 19% beneficiary coinsurance. The July 2026 limit was $479.191. Commercial payers use their own fee schedules.

How many units of J0217 can be billed per day?

The practitioner Medically Unlikely Edit is 150 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J0217?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Lamzede (Chiesi USA, Inc.). For example NDC 10122-0180-02 (package size 1) equals 10 billing units of J0217.

Does J0217 have NCCI bundling edits?

No active practitioner PTP pairs list J0217 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.